Getting to better prescription drug information

Journal of General Internal Medicine

Volumn 27, Issue 12, 2012, Pages 1582-1584

  Woloshin, Steven ^a,b   Schwartz, Lisa M ^a,b  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ACUTE LIVER FAILURE; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; COMPREHENSION; CONSUMER; DEPRESSION; DRUG INFORMATION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEART INFARCTION; HUMAN; LINGUISTICS; LIVER FUNCTION; NIGHTMARE; PRESCRIPTION; READING; SUICIDAL IDEATION; UNSPECIFIED SIDE EFFECT;

COMPREHENSION; DRUG LABELING; FEMALE; HUMANS; MALE; MULTILINGUALISM; PATIENT EDUCATION AS TOPIC; PRESCRIPTION DRUGS;

EID: 84873571089     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-012-2222-2     Document Type: Article

References (20)

1. Avorn J. Powerful medicines: The benefits, risks and costs of prescription drugs. New York: Random House; 2005.
2. Cooper Bailey S, Sarkar U, Hm Chen A. Evaluation of language concordant, patient-centered drug label instructions. J Gen Intern Med. 2012; doi:10.1007/s11606-012-2035-3.
3. Wolf M, Davis T, Curtis L. Effect of standardized, patient-centered label instructions to improve comprehension of prescription drug use. Med Care. 2011;49:5.
4. Wolf M, King J, Wilson E. Usability of FDA-approved medication guides. J Gen Intern Med. 2012; doi:10.1007/s11606-012-2068-7.
5. Aikin K, O'Donoghue A, Swasy J, Sullivan H. Randomized trial of risk information formats in direct-to-consumer prescription drug advetisements. Med Decis Making. 2011;31:E23-33.
6. Fischhoff B. Communicating risks and benefits: An evidence-based user's guide. In: Brewer N, Downs J, eds. U.S. Food and Drug Administration, U.S Department of Health and Human Services; 2011
7. Nicolson D, Knapp P, Raynor D, Spoor P. Written information about individual medicines for consumers. Cochrane Database Syst Rev. 2009 (11).
8. Cohen R, Brown R. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program in practice: does it really inform patients and limit risk? Am J Kidney Dis. 2012;59:3.
9. Schwartz L, Woloshin S, Welch H. The drug facts box: providing consumers with simple tabular data on drug benefit and harm. Med Decis Making. 2007;27.
10. Schwartz LM, Woloshin S. Lost in transmission - FDA drug information that never reaches clinicians. N Engl J Med. 2009;361:1717-20.
11. Schwartz LM, Woloshin S. Communicating uncertainties about prescription drugs to the public. A national randomized trial. Arch Intern Med. 2011;171:1463-8.
12. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med. 2009;150:516-27.
13. Woloshin S, Schwartz L, Tremmel J, Welch H. Direct to consumer drug advertisements: what are Americans being sold? Lancet. 2001;358:1141-6.
14. Woloshin S, Schwartz L, Welch H. The value of benefit data in direct-toconsumer drug ads. Health Affairs 2004:W234-45.
15. Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment: a randomized trial. Ann Intern Med. 2011;155:87-96.
16. U.S. Food and Drug Administration. Disclosing risk information in consumer-directed print advertisements: Brief summary, Example of fictitious highlights of prescribing information, Example of fictitional highlights of prescribing information (based on proposed physicianlabeling rule) translated in consumer-friendly language and formatted for use in consumer directed. February 4, 2004. Available at: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm064956.htm. Accessed August 10, 2012.
17. Kritz FL. FDA on drug ads: less is more. Washington Post. 2004;10:2004.
18. Stacey D, Bennett C, Barry M, Col N, Eden K, Holmes-Rovner M, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011(10).
19. Minutes of the risk communication advisory committee. FDA . April 30 - May 1, 2009 http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/RiskCommunicationAdvisoryCommittee/UCM190625.pdf.
20. Public Law 111 - 148. Patient Protection and Affordable Care Act. Section 3507. Enacted March 23, 2010.